New hope for kids with Hard-to-Treat brain tumors: targeted drug shows promise

NCT ID NCT03363217

First seen Apr 29, 2026 · Last updated Apr 29, 2026

Summary

This study tests a daily oral drug called trametinib in children and young adults (ages 1 month to 25 years) with certain brain or nerve tumors that have not responded to other treatments. The goal is to see if the drug can shrink tumors or stop them from growing. The study includes four groups of patients, including those with a condition called neurofibromatosis type 1. Researchers will also monitor quality of life and thinking skills.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLEXIFORM NEUROFIBROMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alberta Children's Hospital

    Calgary, Alberta, T3B 6A8, Canada

  • CHU Sainte-Justine

    Montreal, Quebec, H3T 1C5, Canada

  • CHU de Québec

    Québec, Quebec, G1V 4G2, Canada

  • Children and Women's Health Centre of British Colombia

    Vancouver, British Columbia, Canada

  • IWK Health Centre

    Halifax, Nova Scotia, Canada

  • Montreal Children's Hospital

    Montreal, Quebec, H4A 3J1, Canada

  • The Hospital for Sick Children

    Toronto, Ontario, M5G 1X8, Canada

Conditions

Explore the condition pages connected to this study.